ArticleInsights into imaging2026
Prognostic value of Node-RADS scoring in stage IIICr cervical cancer: development and validation of novel nomograms.
Article in Insights into imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
objectivesThis study aimed to establish and validate nomograms integrating the Node-Reporting and Data System (Node-RADS) score and clinical variables to predict overall survival (OS) and progression-free survival (PFS) in patients with International Federation of Obstetrics and Gynecology (FIGO) 2018 stage IIICr cervical cancer receiving definitive chemoradiotherapy. MATERIALS AND
methodsA retrospective two-center cohort study was conducted, enrolling eligible patients treated between March 2011 and December 2022. Nomograms were established based on least absolute shrinkage and selection operator (LASSO) regression, and Cox regression was used to identify prognostic features. The performance of the nomograms was assessed using receiver operating characteristic curves (ROC), calibration curves, and decision curve analysis (DCA).
resultsA total of 307 eligible patients were analyzed. For OS, independent prognostic factors included para-aortic lymph node (PALN) metastasis, non-squamous histology, Node-RADS score, and lymph node (LN) boost irradiation ≥ 60 Gy EQD2 (Equivalent dose in 2Gy fractions); for PFS, these were T stage, non-squamous histology, and LN boost irradiation ≥ 60 Gy EQD2. Nomograms outperformed FIGO 2009/2018 staging in discrimination and clinical utility, with calibration curves showing good agreement between predicted and observed outcomes. Kaplan-Meier analysis linked higher Node-RADS scores, PALN metastasis, > 3 positive LNs, and LN boost irradiation < 60 Gy EQD2 to poorer OS and PFS.
conclusionA nomogram incorporating the Node-RADS score, which is significantly associated with survival, can serve as a potential prognostic marker to assist clinicians in making informed decisions and developing individualized treatment strategies. Notably, the inherent treatment-selection bias in the retrospective design limits its direct therapeutic implications. CRITICAL RELEVANCE STATEMENT: Node-RADS-based nomograms offer superior risk stratification and prognosis prediction for stage IIICr cervical cancer patients. KEY POINTS: The nomogram incorporating the Node-Reporting and Data System (Node-RADS) score can serve as a potential prognostic marker to assist clinicians. The nomogram incorporating the Node-RADS score, which integrated clinicopathological data and therapies, outperformed Federation of Obstetrics and Gynecology (FIGO) staging in discriminative ability and clinical utility. Higher Node-RADS scores correlated with worse survival outcomes of patients, and lymph node (LN) boost irradiation ≥ 60 Gy EQD2 might provide survival benefits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.